GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Research & Development

Exelixis (LTS:0IJO) Research & Development : $1,038 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Exelixis Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Exelixis's Research & Development for the three months ended in Mar. 2024 was $228 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $1,038 Mil.

Exelixis Research & Development Historical Data

The historical data trend for Exelixis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Research & Development Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.96 547.85 693.72 891.81 1,044.07

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.25 232.57 332.59 244.67 227.69

Exelixis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,038 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis  (LTS:0IJO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Exelixis Research & Development Related Terms

Thank you for viewing the detailed overview of Exelixis's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (LTS:0IJO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Research & Development
Comparable Companies
RVMD HALO BPMC IONS JAZZ BBIO VKTX CYTK APLS MDGL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
EXEL:USA EX9:Germany
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Website
https://www.exelixis.com
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (LTS:0IJO) Headlines

No Headlines